These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
30. Cardiac metallothionein synthesis in streptozotocin-induced diabetic mice, and its protection against diabetes-induced cardiac injury. Song Y; Wang J; Li Y; Du Y; Arteel GE; Saari JT; Kang YJ; Cai L Am J Pathol; 2005 Jul; 167(1):17-26. PubMed ID: 15972948 [TBL] [Abstract][Full Text] [Related]
31. Cardiac natriuretic peptide deficiency sensitizes the heart to stress-induced ventricular arrhythmias via impaired CREB signalling. Hall EJ; Pal S; Glennon MS; Shridhar P; Satterfield SL; Weber B; Zhang Q; Salama G; Lal H; Becker JR Cardiovasc Res; 2022 Jul; 118(9):2124-2138. PubMed ID: 34329394 [TBL] [Abstract][Full Text] [Related]
32. The antioxidant function of metallothionein in the heart. Kang YJ Proc Soc Exp Biol Med; 1999 Dec; 222(3):263-73. PubMed ID: 10601885 [TBL] [Abstract][Full Text] [Related]
33. Pressure-independent cardiac hypertrophy in mice with cardiomyocyte-restricted inactivation of the atrial natriuretic peptide receptor guanylyl cyclase-A. Holtwick R; van Eickels M; Skryabin BV; Baba HA; Bubikat A; Begrow F; Schneider MD; Garbers DL; Kuhn M J Clin Invest; 2003 May; 111(9):1399-407. PubMed ID: 12727932 [TBL] [Abstract][Full Text] [Related]
34. Metallothionein prevention of arsenic trioxide-induced cardiac cell death is associated with its inhibition of mitogen-activated protein kinases activation in vitro and in vivo. Miao X; Tang Z; Wang Y; Su G; Sun W; Wei W; Li W; Miao L; Cai L; Tan Y; Liu Q Toxicol Lett; 2013 Jul; 220(3):277-85. PubMed ID: 23664956 [TBL] [Abstract][Full Text] [Related]
35. Diabetes- and angiotensin II-induced cardiac endoplasmic reticulum stress and cell death: metallothionein protection. Xu J; Wang G; Wang Y; Liu Q; Xu W; Tan Y; Cai L J Cell Mol Med; 2009 Aug; 13(8A):1499-512. PubMed ID: 19583814 [TBL] [Abstract][Full Text] [Related]
36. Puerarin attenuates pressure overload-induced cardiac hypertrophy. Yuan Y; Zong J; Zhou H; Bian ZY; Deng W; Dai J; Gan HW; Yang Z; Li H; Tang QZ J Cardiol; 2014 Jan; 63(1):73-81. PubMed ID: 23906530 [TBL] [Abstract][Full Text] [Related]
37. Prior increase in metallothionein levels is required to prevent doxorubicin cardiotoxicity. Sun X; Kang YJ Exp Biol Med (Maywood); 2002 Sep; 227(8):652-7. PubMed ID: 12192109 [TBL] [Abstract][Full Text] [Related]
38. Atrial natriuretic peptide affects cardiac remodeling, function, heart failure, and survival in a mouse model of dilated cardiomyopathy. Wang D; Gladysheva IP; Fan TH; Sullivan R; Houng AK; Reed GL Hypertension; 2014 Mar; 63(3):514-9. PubMed ID: 24379183 [TBL] [Abstract][Full Text] [Related]
39. Calsarcin-1 protects against angiotensin-II induced cardiac hypertrophy. Frank D; Kuhn C; van Eickels M; Gehring D; Hanselmann C; Lippl S; Will R; Katus HA; Frey N Circulation; 2007 Nov; 116(22):2587-96. PubMed ID: 18025526 [TBL] [Abstract][Full Text] [Related]
40. Adverse effects of high glucose and free fatty acid on cardiomyocytes are mediated by connective tissue growth factor. Wang X; McLennan SV; Allen TJ; Tsoutsman T; Semsarian C; Twigg SM Am J Physiol Cell Physiol; 2009 Dec; 297(6):C1490-500. PubMed ID: 19625611 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]